News

Visby Medical™ today announced Terri S. Bresenham and Scott Edward Mendel have been appointed to the company’s Board of Directors.

Integration of the Visby Medical sexually transmitted infections (STI) panel into clinical practice could significantly reduce over- and under-treatment of Chlamydia, Gonorrhea, and Trichomonas

Significant improvement to patient care and antimicrobial stewardship with appropriate use of antibiotics may be achieved through the use of rapid point-of-care PCR STI testing.

Thomas Prescott, former president and chief executive officer (CEO) of Align Technology and Cardiac Pathways, will join as the company’s new chairman of the board.

Visit our booth on the show floor or stop by our virtual booth via the ACEP app to set an appointment to learn about our revolutionary palm-sized PCR for three critical sexual health targets — chlamydia, gonorrhea, and trichomonas.

Visby Medical™, a leading medical diagnostic company, today announced the appointment of John W. Kuo as the company’s new Chief Legal Officer. An experienced veteran in corporate law, Kuo brings more than 30 years of experience across multiple industries, including nearly 20 years in the healthcare industry.

The Visby Medical™ instrument-free Reverse Transcription (RT)-Polymerase Chain Reaction (PCR) COVID-19 test was granted Emergency Use Authorization (EUA) by the FDA

The Visby Medical Sexual Health Click Test is the first instrument-free PCR test for the detection of Chlamydia, Gonorrhea, and Trichomonas, with results available within 30 minutes, during the patient visit.

Authors: Sheldon R Morris, Claire C Bristow, Michael R Wierzbicki, Mark Sarno, Lenore Asbel, Audrey French, Charlotte A Gaydos, Lydie Hazan, Leandro Mena, Purnima Madhivanan, Susan Philip, Saara Schwartz, Constance Brown, David Styers, Toni Waymer, Jeffrey D Klausner Published: November 23, 2020 Summary: Background The objective of this study was to measure the performance of… Continue reading Lancet Publishes study measuring Visby Medical Sexual Health Click Test performance

Visby Medical appoints Mark Ibison as Chief Financial Officer, Christopher J. Jowett as Chief Commercial Officer, and Alicia Zuiker as Chief People Officer

The global COVID-19 pandemic touches and disrupts every aspect of life and livelihood across geographies. Despite progress with public health practices and vaccinations, our personal and professional futures face uncertainty. Inconsistent and ambiguous re-opening procedures hinder a robust return to pre-pandemic routines that can restore productivity and economic health.

With the COVID-19 vaccine being distributed and overall infection rates stabilizing, people are beginning to talk about life after the pandemic. Anxious to get back to some kind of normality, even if it means adopting a new normal that includes continued mask wearing and physical distancing, businesses are making plans to open back up.

Expanding critical access to the only single-use, rapid PCR test, at the point of care.

Visby Medical pairs speed with the accuracy of gold-standard PCR testing in a single-use device, so doctors don’t have to fight blind.

A study of the performance of the Visby Medical Sexual Health Test, a single-use, point-of-care PCR device.

PCR’s superpower lies in its super sensitivity, which enables it to sniff out even low levels of a pathogen in minutes. Here’s how it works.

Visby Medical, an infectious disease diagnostic company, received funding from the National Institutes of Health as part of the organization’s Rapid Acceleration of Diagnostics (RADx) program, an initiative that aims to combat SARS-CoV-2 and increase national testing capacity for COVID-19.

Personal PCR could one day become as common as the common cold. In the future, the device will deliver lab accurate results anywhere and to anyone — forever changing our relationship with diagnostics.

Seven-year-old startup emerges from stealth mode, provides adaptable and rapid testing technology to frontline lab personnel fighting the pandemic

Now that Visby has received EUA for our Personal PCR Test to be deployed in moderate-complexity CLIA-certified labs, we’re taking it to the front line of the fight against COVID-19. Each device is personal to individual patients, with results delivered to a lab technician in less than 30 minutes.

As appeared in NIH website 8/5/20